Foundayo Side Effects: What the Label and Trials Actually Report

Foundayo (orforglipron) is a once-daily pill from Eli Lilly, approved by the FDA on April 1, 2026 for adults with obesity, or adults with overweight plus at least one weight-related health condition [1][2]. It belongs to the GLP-1 receptor agonist family, the same broad family as Ozempic, Wegovy, Mounjaro and Zepbound, and its side effect profile looks like that family’s: mostly stomach and gut complaints that show up while the dose is going up.

What makes Foundayo unusual is how much detail its label gives you. Because the FDA approved it on data from more than 3,100 treated patients across two large trials, the prescribing information breaks down almost every reaction by dose. This article walks through those numbers.

Nothing here is medical advice. It summarizes what the FDA-approved prescribing information, its Instructions for Use and the published trials report — not what any individual should do. Follow the directions on your own prescription and your prescriber’s instructions, which may differ from the general schedule described here. Whether Foundayo is right for you, and what to do about any symptom, is a conversation with a healthcare provider.

What are the most common Foundayo side effects?

The label’s Table 1 lists reactions that happened in at least 5% of people taking Foundayo and more often than on placebo. The numbers come from pooling ATTAIN-1 and ATTAIN-2: 3,155 adults on Foundayo and 1,576 on placebo, followed for up to 72 weeks [1].

Side effect	Placebo	5.5 mg	9 mg	17.2 mg
Nausea	10%	26%	34%	35%
Constipation	9%	20%	27%	24%
Diarrhea	11%	21%	23%	25%
Vomiting	4%	13%	21%	24%
Indigestion (dyspepsia)	4%	12%	16%	13%
Stomach pain	7%	13%	14%	14%
Headache	7%	8%	9%	9%
Bloating	3%	7%	9%	8%
Fatigue	4%	6%	7%	9%
Burping	1%	6%	8%	8%
Acid reflux (GERD)	2%	6%	6%	7%
Gas	2%	5%	6%	6%
Hair loss	2%	4%	4%	5%

Two patterns jump out. First, almost everything gets more common as the dose goes up, and vomiting roughly doubles between the 5.5 mg and 17.2 mg doses. Second, the placebo column is not zero. Nine percent of people taking a dummy pill reported constipation and 11% reported diarrhea. Some of what people experience on any weight-management drug comes from eating differently, not from the drug.

Taken as a group, gastrointestinal reactions of any kind occurred in 60% of people on 5.5 mg, 68% on 9 mg and 69% on 17.2 mg, against 37% on placebo [1]. That sounds alarming until you look at severity: among the Foundayo patients who had GI reactions, 60% rated them mild, 36% moderate and only 4% severe [1].

How long do the side effects last?

The label is direct but not precise: “The incidence of nausea, vomiting, and diarrhea was higher during the dose escalation period and decreased over time” [1].

That is the same pattern reported for other GLP-1 drugs, and it is the whole reason Foundayo has a six-step dose ladder in the first place. The label starts everyone at 0.8 mg and allows an increase no sooner than every 30 days, up to a maximum of 17.2 mg, explicitly to reduce gastrointestinal adverse reactions [1]. Reaching the top dose takes at least five steps and about five months.

The label does not promise the symptoms go away, and it sets no expectation that anyone continue through them. Any decision about slowing down, pausing or changing a dose is a prescriber’s to make with the patient.

How many people quit Foundayo because of side effects?

Eight percent of people on Foundayo permanently discontinued because of an adverse reaction, against 3% on placebo. By dose, that was 6% at 5.5 mg, 9% at 9 mg and 10% at 17.2 mg. Most of those discontinuations were gastrointestinal [1]. Looking only at GI reactions as the cause, discontinuation was 3%, 6% and 6% across the three doses versus 0.7% on placebo [1].

There is one useful comparison point. In ACHIEVE-3, the only head-to-head Phase 3 trial between two GLP-1 pills, 8.7% and 9.7% of people on the two Foundayo doses stopped for adverse events, compared with 4.5% and 4.9% on oral semaglutide’s 7 mg and 14 mg diabetes doses [3]. Foundayo produced bigger A1C and weight changes in that trial, but it was harder on the stomach. That trade-off is real, and it was run in people with type 2 diabetes, not in a general weight-management population.

Novo Nordisk, which makes semaglutide, published an indirect analysis called ORION in April 2026 claiming orforglipron carried roughly 14 times higher odds of stopping because of GI side effects compared with the 25 mg Wegovy tablet [4]. That was a manufacturer-sponsored comparison across two separately run trials, not a head-to-head study, and it should be read with that in mind.

What is the boxed warning on Foundayo?

Foundayo carries the same class boxed warning as other GLP-1 receptor agonists: a risk of thyroid C-cell tumors seen in rodents. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 [1].

There is an unusual wrinkle worth understanding. The Foundayo warning states that orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodent studies. The rodent tumors that generated this class warning came from GLP-1 drugs that do activate the rodent receptor. Because orforglipron does activate the human GLP-1 receptor, the FDA applied the class warning anyway, saying the human relevance of the rodent finding has not been determined [1]. The label also notes that routine calcitonin blood tests or thyroid ultrasounds are of uncertain value and may lead to unnecessary procedures.

What serious side effects does the label warn about?

Beyond the boxed warning, the label lists nine warnings and precautions. Most were rare in the trials, with placebo rates for comparison [1]:

• Acute pancreatitis. Six adjudicated events in six Foundayo patients, a rate of 0.14 per 100 years of exposure, against two events in one placebo patient (0.04 per 100 patient-years).
• Acute kidney injury. 0.2% versus 0.05% on placebo. Usually linked to dehydration from vomiting or diarrhea.
• Gallbladder problems. Gallstones in 1% versus 0.7%; acute gallbladder inflammation in 0.4% versus 0.3%.
• Low blood sugar. In the type 2 diabetes trial, 2% versus 0.2% on placebo. Among people also taking a sulfonylurea, 7% versus 0.5% of those not on one, with one severe case. In the trial without diabetes, glucose below 54 mg/dL occurred in 0.6% of Foundayo patients and no placebo patients.
• Allergic reactions including anaphylaxis. 0.5% versus 0.3%.
• Diabetic retinopathy complications in people with type 2 diabetes.
• Pulmonary aspiration during anesthesia or deep sedation. The label says available data are not sufficient to recommend changing fasting rules or pausing the drug before a procedure, and instructs patients to tell their care team they are taking it [1].
• Suicidal behavior and ideation, a class-wide monitoring instruction.
• Heart rate increase, covered below.

The FDA also attached postmarketing requirements at approval. The agency’s NDA 220934 approval letter, signed April 1 and posted April 14, 2026, states that “only a clinical trial (rather than a nonclinical or observational study) will be sufficient to assess a signal of a serious risk of retained gastric contents and to identify an unexpected serious risk for major adverse cardiovascular events (MACE), drug-induced liver injury (DILI), and exposure to orforglipron during lactation” [5]. Separate required studies include a milk-only lactation study and a clinical pharmacology trial measuring the effect of withholding doses and of fasting duration on retained gastric contents, to inform recommendations on pulmonary aspiration risk [5][11]. Part of that question was answered on April 16, 2026 when ACHIEVE-4, the longest Foundayo trial at 104 weeks and 2,749 participants, reported no hepatic safety signal and a hazard ratio of 0.84 for major cardiovascular events against insulin glargine [6]. The broader postmarketing program is still running.

Does Foundayo raise your heart rate?

Modestly. Mean heart rate rose 4 to 5 beats per minute from baseline versus 0.5 beats per minute on placebo, and reactions coded as tachycardia were reported in 3% of Foundayo patients versus 0.9% on placebo [1].

At the same time blood pressure fell. Across the three doses, systolic pressure dropped 3.7 to 4.9 mm Hg more than placebo in ATTAIN-1 and 2.5 to 3.0 mm Hg more in ATTAIN-2 [1]. Low blood pressure was reported in 2% versus 0.5% on placebo, and was more common in people already taking blood pressure medicine (4%) than in those who were not (1%) [1]. A small heart-rate rise alongside a blood-pressure fall is a familiar GLP-1 class pattern.

Does Foundayo cause hair loss?

It is in the label, at 4% to 5% versus 2% on placebo [1]. The label goes further than most: it says hair-loss reactions “were associated with weight reduction” rather than with the drug directly, and it gives a sex breakdown that is striking. Seven percent of women on Foundayo reported hair loss versus 0.9% of men. On placebo, the figures were 3% of women and 0.7% of men [1].

In other words, women were about eight times more likely than men to report it on drug, and women on placebo reported it more often than men on drug. Rapid weight loss from any cause is a known trigger for telogen effluvium, the temporary shedding that happens when a lot of hair follicles shift into a resting phase at once.

What about blood test changes?

Foundayo raised pancreatic amylase by an average of 16% to 20% and lipase by 26% to 31% from baseline, versus 3% and 4% on placebo [1]. These are the enzymes doctors check when they suspect pancreatitis. The label says the clinical significance of these elevations, without other signs of pancreatitis, is unknown.

Less common reactions recorded in the trials include dizziness (4% versus 3%), altered taste (0.9% versus 0.3%) and dysesthesia, an odd skin sensation, at 1% on the top dose versus 0.1% on placebo [1].

What drug interactions does Foundayo have?

This is where Foundayo genuinely differs from injectable GLP-1s. Orforglipron is a small molecule cleared mainly by the liver enzyme CYP3A4, so other drugs that block or speed up that enzyme change your blood levels [1]:

• Strong CYP3A4 inhibitors: the label caps Foundayo at 9 mg once daily. Clarithromycin raised orforglipron exposure 3.5-fold.
• OATP1B inhibitors: cyclosporine raised exposure 2.6-fold. The label says to avoid strong CYP3A4 inhibitors that also inhibit OATP1B, naming ritonavir as the example.
• Strong CYP3A4 inducers: avoid. Carbamazepine cut exposure by 82%.
• Simvastatin: Foundayo raised exposure to the active metabolite simvastatin acid roughly two- to 2.5-fold, so the label says not to exceed simvastatin 20 mg once daily.
• Esomeprazole 40 mg: no effect, so acid reducers are not a problem the way they can be with some oral drugs.

Because Foundayo delays stomach emptying, it can also affect how other oral medicines are absorbed generally.

One interaction matters enough that Lilly put it in the consumer materials: the label advises women using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for 30 days after starting Foundayo and for 30 days after each dose increase [1][2]. Because Foundayo has five dose steps above the starting dose, someone titrating all the way up could face several separate 30-day windows. The label notes the effect on contraceptive absorption has not actually been tested in a clinical trial.

Are there people who should not take Foundayo?

The label lists contraindications and use restrictions rather than advice, and a prescriber applies them [1]:

• Contraindicated with a personal or family history of medullary thyroid carcinoma, or MEN 2.
• Contraindicated with a serious hypersensitivity reaction to orforglipron or any ingredient.
• Not recommended alongside another GLP-1 receptor agonist.
• Not recommended in severe gastroparesis.
• Not recommended in severe liver impairment (Child-Pugh C), because exposure rose 4.6-fold.
• Discontinue when pregnancy is recognized; weight loss offers no benefit in pregnancy and may harm a fetus. Not recommended while breastfeeding.
• Safety and effectiveness have not been established in children.

Kidney impairment is the interesting exception. No dose change is recommended for any level of kidney impairment, including end-stage renal disease, because only about 1% of a dose leaves through urine and 87% leaves in feces [1].

What do real patients say?

Trial numbers describe averages. Patient reports describe texture, and they are anecdote, not evidence.

On Drugs.com, Foundayo carried an average rating of 7.0 out of 10 from 40 reviews, with 50% reporting a positive experience and 13% negative, and nausea, constipation and fatigue named as the most commonly mentioned side effects [7]. That figure is carried forward from an earlier check rather than re-verified on September 14, 2026 — Drugs.com blocks automated retrieval — so treat it as approximate and check the page directly. Forty reviews is in any case a small sample from early adopters and cannot be compared meaningfully against the hundreds of reviews the older brands carry.

Across the r/FoundayoPill and r/FoundayoUS communities between April and September 2026, a few themes recur [8]. Constipation is the complaint people who have used injectables most often say is worse on the pill. Early fatigue is common enough that several posters plan around it. A minority describe mood changes, disturbed sleep or vivid dreams, and one widely read post described sleep disruption and mood swings on the 2.5 mg dose that resolved within about 48 hours of stopping. People who came off high-dose tirzepatide and restarted Foundayo near the bottom of the ladder frequently report hunger returning and a few pounds of regain while they titrate back up.

Against that, the most-cited benefit is not efficacy at all: no needles, no refrigeration, and no rules about when you take it. The label simply says once daily, with or without food [1], which is the practical difference from oral semaglutide tablets that must be taken fasting with no more than 4 ounces of water and a 30-minute wait.

What should you do if you get side effects?

Tell a healthcare provider. That is the only answer this article can responsibly give, and it is what the label and Medication Guide say too.

A few things are worth knowing so you can describe what you are experiencing accurately. The label directs that if seven or more consecutive doses are missed, prescribers reinitiate dosage escalation at a lower dosage to reduce the risk of GI reactions [1] — so a gap matters clinically and is worth mentioning. The label also directs patients to inform any surgeon or anesthesiologist of any planned surgery or procedure while taking Foundayo [1]. And severe, persistent stomach pain that may radiate to the back, with or without vomiting, is the symptom the label singles out for pancreatitis.

None of the above is a direction to take, skip, delay or change any dose. It is a summary of what the FDA-approved label says; your own prescription and your prescriber’s instructions govern.

Sources

1. FOUNDAYO (orforglipron) tablets, US Prescribing Information, revised 7/2026 — Eli Lilly and Company
2. FDA Approves Lilly’s Foundayo (orforglipron), the Only GLP-1 Pill… — Eli Lilly, April 1, 2026
3. Orforglipron versus oral semaglutide in type 2 diabetes (ACHIEVE-3) — The Lancet, February 26, 2026
4. Novo Nordisk ORION indirect comparison coverage — community summary of Novo Nordisk’s April 2, 2026 announcement
5. NDA 220934 approval letter, Foundayo (orforglipron) tablets — US Food and Drug Administration, signed April 1, 2026, posted April 14, 2026
6. ACHIEVE-4, the longest Phase 3 study of Foundayo — Eli Lilly, April 16, 2026
7. Foundayo user reviews — Drugs.com
8. r/FoundayoPill one-month review, previous GLP-1 use — Reddit, May 6, 2026
9. ATTAIN-1 full results — New England Journal of Medicine, November 6, 2025
10. ATTAIN-MAINTAIN results — Nature Medicine, May 13, 2026
11. FDA seeks additional safety data from Lilly on weight-loss pill Foundayo — Reuters, April 14, 2026